Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...
"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...
In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...
"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
People with intermediate-risk scores on coronary artery calcium testing who received statins and intensive health coaching ...
Investors looking for safe havens in a dangerous market. China EV players, FedEx and Micron earnings next week.
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive
Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback